The clinical profile and outcomes of drug resistant tuberculosis in Central Province of Zambia
- PMID: 38556907
- PMCID: PMC10983631
- DOI: 10.1186/s12879-024-09238-8
The clinical profile and outcomes of drug resistant tuberculosis in Central Province of Zambia
Abstract
Background: The emergence of Drug Resistant Tuberculosis (DR-TB) is one of the main public health and economic problems facing the world today. DR-TB affects mostly those in economically productive years and prevents them from being part of the workforce needed for economic growth. The aim of this study was to determine the Clinical Profile and Outcomes of DR-TB in Central Province of Zambia.
Methods: This was a retrospective cross sectional study that involved a review of records of patients with confirmed DR-TB who were managed at Kabwe Central Hospital's Multi-Drug Resistant TB (MDR-TB) Ward from the year 2017 to 2021. 183 patients were managed during this period and all were recruited in the study. Data was collected from DR-TB registers and patient files and then entered in SPSS version 22 where all statistical analyses were performed.
Results: The study revealed that the prevalence of DR-TB among registered TB patients in Central Province was 1.4%. Majority of those affected were adults between the ages of 26 and 45 years (63.9%). The study also found that more than half of the patients were from Kabwe District (60.7%). Other districts with significant number of cases included Kapiri Mposhi 19 (10.4%), Chibombo 12 (6.6%), Chisamba 10 (5.5%), Mumbwa 7 (3.8%) and Mkushi 7 (3.8%). Furthermore, the analysis established that most of the patients had RR-TB (89.6%). 9.3% had MDR-TB, 0.5% had IR-TB and 0.5% had XDR-TB. RR-TB was present in 93.8% of new cases and 88.9% of relapse cases. MDR-TB was present in 6.2% of new cases and 10% of relapse cases. With regard to outcomes of DR-TB, the investigation revealed that 16.9% of the patients had been declared cured, 45.9% had completed treatment, 6% were lost to follow up and 21.3% had died. Risk factors for mortality on multivariate analysis included age 36-45 years (adjusted odds ratio [aOR] 0.253, 95% CI [0.70-0.908] p = 0.035) and male gender (aOR 0.261, 95% CI [0.107-0.638] p = 0.003).
Conclusion: The research has shown beyond doubt that the burden of DR-TB in Central Province is high. The study recommends putting measures in place that will help improve surveillance, early detection, early initiation of treatment and proper follow up of patients.
Keywords: Central province; Clinical Profile; Drug resistant tuberculosis; Zambia.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Trends of drug-resistant tuberculosis and risk factors to poor treatment-outcome: a database analysis in Littoral region-Cameroon, 2013-2022.BMC Public Health. 2024 Nov 18;24(1):3195. doi: 10.1186/s12889-024-20585-8. BMC Public Health. 2024. PMID: 39558329 Free PMC article.
-
Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.BMC Infect Dis. 2017 Aug 16;17(1):573. doi: 10.1186/s12879-017-2662-8. BMC Infect Dis. 2017. PMID: 28814276 Free PMC article.
-
Risk factors for poor outcomes in patients with drug-resistant tuberculosis: a 6-year multicenter prospective study in Zhejiang, China.BMC Infect Dis. 2025 Mar 27;25(1):422. doi: 10.1186/s12879-025-10802-z. BMC Infect Dis. 2025. PMID: 40140735 Free PMC article.
-
Trends in drug-resistant tuberculosis in China: data from a clinical tuberculosis centre.Int J Tuberc Lung Dis. 2017 Sep 1;21(9):990-995. doi: 10.5588/ijtld.17.0086. Int J Tuberc Lung Dis. 2017. PMID: 28826447 Review.
-
Prevalence of tuberculosis infection among contacts of drug-resistant tuberculosis patients: A systematic review and meta-analysis.J Infect. 2024 Aug;89(2):106198. doi: 10.1016/j.jinf.2024.106198. Epub 2024 Jun 19. J Infect. 2024. PMID: 38906264
Cited by
-
Chest x-ray features and their associated factors among rifampicin/multi-drug-resistant tuberculosis patients in drug-resistant tuberculosis treatment initiating centers in Addis Ababa, Ethiopia: a retrospective study.BMC Infect Dis. 2025 Aug 2;25(1):974. doi: 10.1186/s12879-025-11344-0. BMC Infect Dis. 2025. PMID: 40753370 Free PMC article.
-
Drug-Resistant Tuberculosis in Rural Eastern Cape, South Africa: A Study of Patients' Characteristics in Selected Healthcare Facilities.Int J Environ Res Public Health. 2024 Nov 30;21(12):1594. doi: 10.3390/ijerph21121594. Int J Environ Res Public Health. 2024. PMID: 39767435 Free PMC article.
-
Predicting Treatment Outcomes in Patients with Drug-Resistant Tuberculosis and Human Immunodeficiency Virus Coinfection, Using Supervised Machine Learning Algorithm.Pathogens. 2024 Oct 24;13(11):923. doi: 10.3390/pathogens13110923. Pathogens. 2024. PMID: 39599476 Free PMC article.
-
Tuberculosis treatment failure: what are the risk factors? A comprehensive literature review.Multidiscip Respir Med. 2025 Jul 4;20(1):1030. doi: 10.5826/mrm.2025.1030. Multidiscip Respir Med. 2025. PMID: 40622307 Free PMC article.
-
Detection of Rifampicin Resistance rpoB Gene Using GeneXpert MTB/RIF Assay in Pulmonary Tuberculosis Cases at Debre Tabor Comprehensive Specialized Hospital, Northwest Ethiopia.J Clin Lab Anal. 2024 Nov;38(22):e25111. doi: 10.1002/jcla.25111. Epub 2024 Oct 10. J Clin Lab Anal. 2024. PMID: 39387506 Free PMC article.
References
-
- Chanda E, Sichilima MA. The impact of stigma on the healthcare of tuberculosis patients in Kitwe. Central Afr J Public Health. 2018;4(6):175–184. doi: 10.11648/j.cajph.20180406. - DOI
-
- Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Elsevier Ltd/Inc/BV; 2013. p. 2013. - PubMed
-
- Isara AR, Akpodiete A. Concerns about the knowledge and attitude of multidrug-resistant tuberculosis among health care workers and patients in Delta state, Nigeria. Niger J Clin Pract. 2015;18(5). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources